These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8690818)

  • 1. Effect of age and gender on pharmacokinetics of atorvastatin in humans.
    Gibson DM; Bron NJ; Richens A; Hounslow NJ; Sedman AJ; Whitfield LR
    J Clin Pharmacol; 1996 Mar; 36(3):242-6. PubMed ID: 8690818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of itraconazole on the pharmacokinetics of atorvastatin.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.
    Whitfield LR; Stern RH; Sedman AJ; Abel R; Gibson DM
    Eur J Drug Metab Pharmacokinet; 2000; 25(2):97-101. PubMed ID: 11112089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
    Malinowski JM
    Am J Health Syst Pharm; 1998 Nov; 55(21):2253-67; quiz 2302-3. PubMed ID: 9825877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of atorvastatin.
    Lennernäs H
    Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.
    Posvar EL; Radulovic LL; Cilla DD; Whitfield LR; Sedman AJ
    J Clin Pharmacol; 1996 Aug; 36(8):728-31. PubMed ID: 8877677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.
    Cilla DD; Gibson DM; Whitfield LR; Sedman AJ
    J Clin Pharmacol; 1996 Jul; 36(7):604-9. PubMed ID: 8844442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Schützer KM; Dorani H; Wall U; Kalies I; Ohlsson L; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.
    Stern RH; Gibson DM; Whitfield LR
    Eur J Clin Pharmacol; 1998 Feb; 53(6):475-8. PubMed ID: 9551707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
    Chung M; Calcagni A; Glue P; Bramson C
    J Clin Pharmacol; 2006 Oct; 46(10):1212-6. PubMed ID: 16988211
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.
    Radulovic LL; Cilla DD; Posvar EL; Sedman AJ; Whitfield LR
    J Clin Pharmacol; 1995 Oct; 35(10):990-4. PubMed ID: 8568017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
    Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
    J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.